Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SERA
SERA logo

SERA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Sera Prognostics Inc (SERA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.160
1 Day change
0.93%
52 Week Range
4.090
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Sera Prognostics (SERA) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below the pre-market move at 2.07 (-3.27%), there is no supportive proprietary buy signal today, insiders have been selling aggressively, and there are no recent news catalysts or financial updates to justify an immediate long-term entry. While the short-term technical setup is mildly constructive, the overall risk/reward is not attractive enough for an impatient buyer seeking a clear buy now decision.

Technical Analysis

Technically, SERA is in a short-term mixed-to-slightly bullish setup. The MACD histogram is positive and expanding, which supports near-term momentum, but RSI_6 at 72.452 suggests the stock is already extended rather than offering a clean low-risk entry. Moving averages are converging, pointing to a transition phase rather than a strong established trend. Price is currently near 2.07, below resistance at R1 2.256 and still above the pivot 1.947, so upside exists but is limited unless it can reclaim and hold above resistance. The pattern-based forecast suggests roughly flat next-day movement, a modest weekly bounce, and weakness over the next month, which does not support an urgent long-term buy.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment looks mildly bullish from positioning because the open interest put-call ratio is very low at 0.1, meaning calls dominate puts. However, actual option volume is zero today, so there is no active trading confirmation from the options market. Implied volatility is high at 121.59, and historical volatility is also elevated at 77.04, which fits a speculative name rather than a steady long-term compounder. Overall, the options structure is bullish on paper but not supported by live participation.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • ["No news in the recent week, so there is no immediate negative headline pressure.", "Options open interest is heavily call-skewed, which suggests some bullish positioning.", "MACD histogram is positive and expanding, indicating improving short-term momentum.", "The stock is still above its pivot support near 1.947."]

Neutral/Negative Catalysts

  • ["Insiders are selling, and the selling amount has increased 2019.12% over the last month.", "No recent news catalysts to drive a rerating or earnings reacceleration.", "No AI Stock Picker or SwingMax signal today or recently.", "RSI is elevated, suggesting the stock is not cheap at current levels.", "Pattern-based forecast shows flat near-term performance and weakness over the next month.", "Hedge funds are neutral with no meaningful accumulation trend.", "No recent congress trading data or politician buying support."]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so a quarter-by-quarter growth assessment is not available. That makes it harder to justify a long-term buy for a beginner investor, since there is no clear evidence here of accelerating revenue, profitability improvement, or a strong latest-quarter season.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrade cycle or target-price momentum to support the stock. Based on the available information, the Wall Street pros view appears mixed to cautious: options positioning is mildly constructive and technical momentum is improving, but insider selling, lack of news, missing financial visibility, and no proprietary buy signals outweigh the bullish side. The cons view is stronger than the pros view at this time.

Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
Wall Street analysts forecast SERA stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.140
sliders
Low
5
Averages
5
High
5
Current: 2.140
sliders
Low
5
Averages
5
High
5
Jefferies
initiated
$5
AI Analysis
2025-12-14
Reason
Jefferies
Price Target
$5
AI Analysis
2025-12-14
initiated
Reason
Jefferies initiated coverage of Sera Prognostics with a Buy rating and $5 price target. Sera is a women's health diagnostics company developing predictive biomarker testing for pregnancy complications, the analyst tells investors in a research note. The firm says the company's flagship product PreTRM offers a simple blood test for predicting individualized risk for spontaneous preterm birth in asymptomatic pregnancies. Jefferies cites PreTRM's first to market clinical validation, "attractive" $1.6B addressable market in the U.S. and its early traction with Elevance partner and Medicaid pilot programs for the Buy rating.

People Also Watch